|
Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. |
| |
|
Consulting or Advisory Role - Baxter (I); Celularity; Sumitomo Dainippon Pharma Co., Ltd. Consulting |
| |
|
Research Funding - 1% FTE to institution (non-PI site collaborator) Novartis |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Exelixis; Genentech/Roche (Inst); Mundipharma (Inst) |
| |
|
Consulting or Advisory Role - A2 Biotherapeutics; Abbvie; Amgen; Ascendis Pharma; Bexion; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Enliven Therapeutics; GT Medical Technologies; NeoImmuneTech; NGM Biopharmaceuticals; Repare Therapeutics; SERVIER; Starpax Medical; Vertex |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Plus Therapeutics |
Research Funding - EMD Serono (Inst); Kintara (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - College of American Pathologists; Research to Practice |
Consulting or Advisory Role - Novocure |
Research Funding - Novocure (Inst) |
Patents, Royalties, Other Intellectual Property - Patent application with Novocure, Ltd. |
Travel, Accommodations, Expenses - Novocure |
(OPTIONAL) Uncompensated Relationships - BMC Neuroscience; National Brain Tumor Registry of China (NBTRC) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Gilead Sciences |
Honoraria - Bayer; Guidepoint Inc; InSightec; Novocure; Orbus Therapeutics; SERVIER; Tango Therapeutics; Telix Pharmaceuticals |
Consulting or Advisory Role - Bayer; Guidepoint Inc; InSightec; Newave Pharmaceutical (I); Novocure; Orbus Therapeutics; SERVIER; Tango Therapeutics; Telix Pharmaceuticals |
Research Funding - Bexion; InSightec; Karyopharm Therapeutics; Kazia Therapeutics; Merck; Radiomedix; Samus Therapeutics; SERVIER |
| |
|
Employment - University of San Francisco |
Patents, Royalties, Other Intellectual Property - University of San Francisco |
| |
|
No Relationships to Disclose |
| |
|
Employment - Alaunos Therapeutics (I); Brii Biosciences (I) |
Stock and Other Ownership Interests - Alaunos Therapeutics (I); Brii Biosciences (I); WuXi Biologics |
Consulting or Advisory Role - Alpha Pharmaceutical; Aucentra Therapeutics; Bioasis Technologies; CarThera; Chimerix; Cure Brain Cancer Foundation; InSightec; Karyopharm Therapeutics; Kazia Therapeutics; Kintara Therapeutics; Merck; Midatech Pharma; Monteris Medical; Mundipharma Research; Samus Therapeutics; Sapience Therapeutics; SERVIER; Sumitomo Dainippon Pharma Oncology; Telix Pharmaceuticals; VBI Vaccines |
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
Other Relationship - Chimerix; VBI Vaccines |